Acute Labetalol Use in Preeclampsia (ALERT)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.
Full description
The investigators seek to asses the effect of obesity (BMI>30) on severe hypertension control in patients with preeclampsia with severe features. The investigators hypothesize that successive administration of 40-60-80 mg of labetolol will reduce time to blood pressure control versus the standard dosing, 20-40-80 mg labetolol, recommended by the American College of Obstetricians and Gynecologists in 2015.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- BMI ≥ 30
- Age ≥ 18 years
- Gestational age ≥ 24 weeks
- Singleton gestation
- One sustained severe range blood pressure at Albany Medical Center
Exclusion criteria
- Known allergic reaction to labetlol
- Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month)
- Obstructive airway disease
- Bradycardia < 70 beats/min
- Heart block > 1st degree or history of heart failure
Trial design
Primary purpose
Allocation
Interventional model
Masking
15 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal